Therapeutic efficacy of orally administration itraconazole in onychomycosis.
- Author:
Jeong Aee KIM
;
Jai Il YOUN
;
Young Hwan KIM
;
Jae Bok JUN
;
Ki Beom PARK
;
Moo Hyung LEE
;
Eui Soo PARK
;
Kee Chan MOON
;
Myeong Nam KIM
;
Jeong Hoon LEE
;
Cheol Heon LEE
;
Jae Hong KIM
- Publication Type:Multicenter Study ; Original Article
- MeSH:
Arthrodermataceae;
Candida;
Glaucoma;
Hospitals, University;
Humans;
Itraconazole*;
Korea;
Liver Function Tests;
Mycology;
Nails;
Onychomycosis*;
Shoulder Pain
- From:Korean Journal of Dermatology
1992;30(4):508-518
- CountryRepublic of Korea
- Language:Korean
-
Abstract:
Botween April 1991 and March 1992, a multicenter open trial was done to evaluate the therapeutic efficacy of itraconazole in the treatment of onychomycosis, 116 patients with onychomycosis diagnosed by clinical and mycological finding were recruited from the 24 university hospitals in Korea. They received 100mg of oral itraconazole once a day until clinical improvement was evident or until 12 months. Response to treatment was evaluated clinically and mycologically. Cure was complete absence of clinical lesions and negative mycological results. Marked improvment was minimal clinical lesions with negative mycology. Moderate improvement was some residual clinical lesions with positive mycology. Unchanged was no clinical response until 4 months after therapy. Obtained results were as follows. 1. Mean duration of treatment was 6.3+/-2.0 months (2-12), and 83 (70.7%) were cured, 27 (23.3%) showed marked improvement, 2 (1.7%) were moderately improved, 3 (2.6%) were unchanged, and 2 (1.7%) were excluded due to the possible side effect of the medication, although they showed moderate improvement. 2. When only fingernails were involved, mean duration of treatment was 5.3+/-2.0 months with cure rate of 81.8%. when toenails were involved, mean duration of treatment was 6.5+/-2.0 months, which was significantly longer than that in fingernail, however cure rate was 66.7%, which was not different from that in fingernail. 3. In cases that Candida spp. were causative organism, 91.7% were cured with marked improvement in another 8.3%. Onychomycosis due to dermatophytes were cured in 72.9%. However, when moulds or T. beigelii were isolated, only one out of six was cured. 4. 9 out of the 116 subjects showed possible side effects during itraconazole treatment. Gastrointestinal troubles were noted in seven, whicn were mostly mild and self-limited, however, in one patient, medications were withdrawn due to continuing gastric upset. In another patient, transient visual disturbance was noted and medications were also withdrawn. However, this patient was already suffereing from glaucoma and causal relationshiop was not established. Shoulder pain was noted in another one, however it was regarded probably unrelated to the drug, and medications were contiued without aggravation of the symptoms. 5. 88 patients were followed with serial biochemical liver function tests for two month interval. None of them showed evidence of hepatic injury during the entire observation period. From the above findings, oral itraconazole was regarded as more effective than the preexisting drugs in the treatment of onychomycosis, and also it was regarded safe in long term therapy.
